Vivos Therapeutics, Inc., a medical technology company, has filed an Amendment No. 1 to Form S-1 with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024, under Registration No. 333-278564. This amendment updates the Incorporation of Certain Information by Reference section of the original Registration Statement on Form S-1 filed on April 9, 2024. The amendment does not reflect any other changes or events post the original filing date. The prospectus relates to the offer for sale of up to 1,737,259 shares of common stock by a selling stockholder, which includes shares underlying common stock purchase warrants issued in private placements on January 9, 2023, and February 20, 2024. Vivos Therapeutics will not receive proceeds from the resale of shares but may receive proceeds upon exercise of the warrants. The company has received regulatory approvals for Medicare reimbursement for its oral medical devices in April 2024. The common stock is listed on Nasdaq under the symbol 'VVOS'.

Vivos Therapeutics, Inc., a medical technology company, has filed an Amendment No. 1 to Form S-1 with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024, under Registration No. 333-278564. This amendment updates the Incorporation of Certain Information by Reference section of the original Registration Statement on Form S-1 filed on April 9, 2024. The amendment does not reflect any other changes or events post the original filing date. The prospectus relates to the offer for sale of up to 1,737,259 shares of common stock by a selling stockholder, which includes shares underlying common stock purchase warrants issued in private placements on January 9, 2023, and February 20, 2024. Vivos Therapeutics will not receive proceeds from the resale of shares but may receive proceeds upon exercise of the warrants. The company has received regulatory approvals for Medicare reimbursement for its oral medical devices in April 2024. The common stock is listed on Nasdaq under the symbol 'VVOS'.